Profile data is unavailable for this security.
About the company
CNBX Pharmaceuticals Inc. is a clinical-stage company specializing in the discovery, development and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. The Company's lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Its anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33, a therapy being developed primarily in two settings: one to reduce tumor cell activity in CRC patients as a standalone in neoadjuvant treatment or window of opportunity at the time after colonoscopy, prior to cancer staging, and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company indents to initiate Phase I/II clinical trials for both candidates: Cannabics SR and RCC-33.
- Revenue in USD (TTM)230.08k
- Net income in USD-1.21m
- Incorporated2004
- Employees2.00
- LocationCNBX Pharmaceuticals Inc#3 Bethesda Metro Center, Suite 700BETHESDA 20814United StatesUSA
- Phone+1 (877) 424-2429
- Websitehttps://cnbxpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seelos Therapeutics Inc | 2.01m | 4.09m | 170.02k | 8.00 | 0.0032 | -- | -- | 0.0844 | 156.15 | 156.15 | 22.91 | -135.50 | 0.2823 | -- | 6.51 | 134,266.70 | 57.34 | -180.05 | -- | -386.76 | -- | -- | 203.13 | -9,612.88 | -- | -608.33 | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| Notable Labs Ltd | 313.00k | -16.74m | 194.64k | 16.00 | -- | 0.0271 | -- | 0.6219 | -2.47 | -2.47 | 0.046 | 0.7439 | 0.0176 | -- | -- | 19,562.50 | -93.89 | -52.02 | -120.26 | -62.09 | 37.70 | 60.19 | -5,346.97 | -3,636.93 | -- | -- | 0.0405 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Propanc Biopharma Inc | 0.00 | -1.87m | 236.97k | 1.00 | -- | -- | -- | -- | -0.0372 | -0.0372 | 0.00 | -0.006 | 0.00 | -- | -- | -- | -1,495.00 | -4,082.63 | -- | -- | -- | -- | -- | -- | -- | -2.55 | -- | -- | -- | -- | 35.61 | -- | -- | -- |
| CNBX Pharmaceuticals Inc | 230.08k | -1.21m | 284.67k | 2.00 | -- | -- | -- | 1.24 | -0.0458 | -0.0458 | 0.0081 | -0.0789 | 0.6201 | -- | -- | 115,040.00 | -325.63 | -73.32 | -- | -99.80 | 14.96 | -- | -525.10 | -3,970.88 | -- | -1.34 | -- | -- | -- | 111.90 | 0.3497 | -- | -- | -- |
| Endonovo Therapeutics Inc | 255.72k | -4.40m | 317.46k | 0.00 | -- | -- | -- | 1.24 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
| Neximmune Inc | 0.00 | -20.62m | 338.73k | 6.00 | -- | 0.4864 | -- | -- | -18.59 | -18.59 | 0.00 | 0.66 | 0.00 | -- | -- | 0.00 | -140.56 | -115.07 | -224.94 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
| GlobeStar Therapeutics Corp | 0.00 | -1.98m | 348.88k | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
| Yield10 Bioscience Inc | 750.00k | -12.70m | 363.66k | 29.00 | -- | -- | -- | 0.4849 | -135.92 | -135.92 | 1.95 | -9.71 | 0.1697 | -- | -- | 25,862.07 | -287.44 | -91.26 | -- | -108.09 | -- | -- | -1,693.60 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
| LadRx Corp | 0.00 | -2.78m | 364.98k | 2.00 | -- | -- | -- | -- | -5.61 | -5.61 | 0.00 | -3.54 | 0.00 | -- | -- | 0.00 | -177.00 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 106.96 | -- | -- | -- |
| Regenerative Medical Technology Grop Inc | 2.87m | -10.15m | 394.98k | 1.00 | -- | -- | -- | 0.1375 | -0.8144 | -0.8144 | 0.2303 | -2.07 | 0.5424 | -- | 76.15 | -- | -191.67 | -192.08 | -- | -- | 68.95 | 60.24 | -353.35 | -821.49 | 0.0257 | -0.0755 | -- | -- | 57.49 | 116.97 | -76.03 | -- | 149.35 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Private Ocean LLCas of 30 Jun 2024 | 9.00 | 0.00% |
| RFP Financial Group LLCas of 30 Sep 2024 | 0.00 | 0.00% |
